Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.660
+0.050 (3.11%)
At close: Mar 9, 2026, 4:00 PM EDT
1.661
+0.001 (0.04%)
After-hours: Mar 9, 2026, 7:59 PM EDT
Ocugen Revenue
In the year 2025, Ocugen had annual revenue of $4.41M with 8.83% growth. Ocugen had revenue of $-193.00K in the quarter ending December 31, 2025, a decrease of -125.26%.
Revenue (ttm)
$4.41M
Revenue Growth
+8.83%
P/S Ratio
123.34
Revenue / Employee
$46,453
Employees
95
Market Cap
544.31M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| REGENXBIO | 170.44M |
| Century Therapeutics | 113.34M |
| Fulcrum Therapeutics | 80.00M |
| Invivyd | 53.43M |
| Verastem | 30.91M |
| YD Bio | 510.36K |
| Lyell Immunopharma | 41.00K |
OCGN News
- 5 days ago - Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 7 days ago - Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa - GlobeNewsWire
- 4 weeks ago - Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer - GlobeNewsWire
- 6 weeks ago - Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock - GlobeNewsWire
- 6 weeks ago - Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering - Benzinga
- 6 weeks ago - Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock - GlobeNewsWire
- 7 weeks ago - Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript - Seeking Alpha